Takahiro Takase

Effect of switching from pioglitazone to the sodium glucose co‐transporter‐2 inhibitor dapagliflozin on body weight and metabolism‐related factors in patients with type 2 diabetes mellitus: An open‐label, prospective, randomized, parallel‐group comparison trial

Y. Kurihara, H. Miyoshi, T. Atsumi, 2018, Diabetes, obesity & metabolism.